Vol.

No.

March 31, 2023Mar 31, 2023

DOWNLOAD THE PDF

Cover Story

Texas federal judge invalidates ACA preventive care mandate—USPSTF, cancer screening, and PrEP in jeopardy

By Matthew Bin Han Ong

Federal agencies can no longer enforce a critical provision in the Affordable Care Act that requires insurance plans to fully pay for preventive services that receive an “A” or “B” grade from the U.S. Preventive Services Task Force—including many new and updated recommendations on screening for cancer and other diseases.

Conversation with The Cancer Letter

Harvard’s Carmel Shachar: Texas ruling that guts ACA preventive care likely to reach Supreme Court—and be upheld

By Matthew Bin Han Ong

Conversation with The Cancer Letter

NYU’s Art Caplan: Texas ruling that nixes USPSTF authority embodies “bigotry, hatred, and ignorance”

By Matthew Bin Han Ong

Conversation with The Cancer Letter Regulatory News

FDA’s Fashoyin-Aje: Draft guidance on accelerated approval urges reliance on randomized controlled trials

By Jacquelyn Cobb

Free In the Archives

Rose Kushner: War correspondent and breast cancer advocate

In Brief

Cheryl L. Willman named Stephen and Barbara Slaggie Executive Director of Mayo Clinic Cancer Programs, director of Mayo Clinic Comprehensive Cancer Center

Northwell establishes comprehensive nurse navigation program

NYU Langone Health’s Perlmutter Cancer Center opens fourth location in Brooklyn, expands services

IU receives $3.3M NCI grant to increase CRC screening in rural Indiana

IU Cancer Center receives new and renewed ACS funding for research, education programs

Jefferson Health’s Lung Cancer Screening Program receives Smoking Treatment Accreditation & Recognition

Funding Opportunities

DoD Rare Cancer Research Program anticipated funding opportunities for FY23

Clinical Roundup

Keytruda + chemo improved PFS as first-line therapy for advanced or recurrent endometrial carcinoma, regardless of MMR status

Phase III RUBY trial demonstrates potential of Jemperli + chemo to redefine treatment of advanced or recurrent endometrial cancer

Sylvester investigators identify potential targets to overcome treatment resistance in TNBC

Kisqali phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in early breast cancer

Phase II study shows surgery is an effective alternative to chemo and radiation for early metastatic testicular cancer

Study shows that patients receiving CAR T-cell therapy have improved QOL six months post-treatment

MD Anderson study shows microbiome-based biomarkers may be used to predict to CAR T-cell therapy response

Study finds diverse differences in microbes in breast tumors from patients of different races

University of Cincinnati scientists develop radiation therapy delivery approach using engineered bacteria

Combination therapy shows potential as novel treatment for adenoid cystic carcinoma in phase II study

Phase I/Ib study shows novel immunotherapy delivery approach safe and beneficial for some melanoma patients with leptomeningeal disease

Drugs & Targets

FDA grants full approval indication for Keytruda for certain patients with advanced MSI-H or dMMR solid tumors

Libtayo + chemo approved by EC for first-line treatment of advanced PD-L1-positive NSCLC

Predictive Oncology and Integra Therapeutics form collaboration focused on gene therapy

ArsenalBio’s lead product advances to clinical manufacturing following Thermo Fisher collaboration

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 33 - September 11, 2026

Texas federal judge invalidates ACA preventive care mandate—USPSTF, cancer screening, and PrEP in jeopardy

Harvard’s Carmel Shachar: Texas ruling that guts ACA preventive care likely to reach Supreme Court—and be upheld

NYU’s Art Caplan: Texas ruling that nixes USPSTF authority embodies “bigotry, hatred, and ignorance”

FDA’s Fashoyin-Aje: Draft guidance on accelerated approval urges reliance on randomized controlled trials

Rose Kushner: War correspondent and breast cancer advocate

In Brief

Cheryl L. Willman named Stephen and Barbara Slaggie Executive Director of Mayo Clinic Cancer Programs, director of Mayo Clinic Comprehensive Cancer Center

Northwell establishes comprehensive nurse navigation program

NYU Langone Health’s Perlmutter Cancer Center opens fourth location in Brooklyn, expands services

IU receives $3.3M NCI grant to increase CRC screening in rural Indiana

IU Cancer Center receives new and renewed ACS funding for research, education programs

Jefferson Health’s Lung Cancer Screening Program receives Smoking Treatment Accreditation & Recognition

Funding Opportunities

DoD Rare Cancer Research Program anticipated funding opportunities for FY23

Clinical Roundup

Keytruda + chemo improved PFS as first-line therapy for advanced or recurrent endometrial carcinoma, regardless of MMR status

Phase III RUBY trial demonstrates potential of Jemperli + chemo to redefine treatment of advanced or recurrent endometrial cancer

Sylvester investigators identify potential targets to overcome treatment resistance in TNBC

Kisqali phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in early breast cancer

Phase II study shows surgery is an effective alternative to chemo and radiation for early metastatic testicular cancer

Study shows that patients receiving CAR T-cell therapy have improved QOL six months post-treatment

MD Anderson study shows microbiome-based biomarkers may be used to predict to CAR T-cell therapy response

Study finds diverse differences in microbes in breast tumors from patients of different races

University of Cincinnati scientists develop radiation therapy delivery approach using engineered bacteria

Combination therapy shows potential as novel treatment for adenoid cystic carcinoma in phase II study

Phase I/Ib study shows novel immunotherapy delivery approach safe and beneficial for some melanoma patients with leptomeningeal disease

Drugs & Targets

FDA grants full approval indication for Keytruda for certain patients with advanced MSI-H or dMMR solid tumors

Libtayo + chemo approved by EC for first-line treatment of advanced PD-L1-positive NSCLC

Predictive Oncology and Integra Therapeutics form collaboration focused on gene therapy

ArsenalBio’s lead product advances to clinical manufacturing following Thermo Fisher collaboration

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login